🔍

SOLARA - Solara Active

📊 NSE: SOLARA 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 13:32

📢 Recent Corporate Announcements

Solara Shareholders Approve Mohanraj Sanjeevi as Whole-time Director with 99.97% Majority

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 10 Mar 2026, 01:02 PM

Solara Active Pharma Sciences Limited has announced the successful passage of a special resolution to appoint Mr. Mohanraj Sanjeevi as a Whole-time Director for a three-year term. The resolution received overwhelming support, with 99.97% of the 26.04 million votes cast in favor. Mr. Sanjeevi's remuneration is set at a fixed Rs. 85 lakh per annum plus a variable component of Rs. 15 lakh. This appointment, effective from January 1, 2026, ensures leadership stability for the company's executive operations.

Special resolution for appointment passed with 99.97% majority (26,032,102 votes in favor).
Mr. Mohanraj Sanjeevi appointed for a 3-year term effective from January 1, 2026, to December 31, 2028.
Total annual remuneration package includes Rs. 85 lakh fixed and Rs. 15 lakh variable pay.
Promoter and institutional investor groups both voted 100% in favor of the resolution.
Overall voter turnout represented 58.64% of the total outstanding shares of the company.

💡 The high level of shareholder support indicates strong confidence in the executive leadership. Investors should view this as a routine governance step providing management continuity.

Solara Active Pharma Closes Non-Operational Brazil Subsidiary; Nil Financial Impact

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Mar 2026, 05:01 PM

Solara Active Pharma Sciences has announced the voluntary deregistration of its wholly owned subsidiary in Brazil, Solara Active Pharma Sciences LTDA. The subsidiary was non-operational and contributed zero revenue and zero net worth to the company's consolidated financials for the fiscal year ended March 31, 2025. This move is part of a routine administrative cleanup of non-material entities. The closure was finalized with the Federal Revenue of Brazil and is effective from July 30, 2025.

Voluntary deregistration of wholly owned subsidiary Solara Active Pharma Sciences LTDA, Brazil.
The subsidiary contributed Nil turnover and Nil net worth to consolidated financials in FY25.
Closure is effective from July 30, 2025, following a period of no business activity.
The entity was classified as a non-material subsidiary with no impact on core operations.

💡 This is a routine administrative update regarding the dissolution of a shell entity. No action is required as there is no impact on the company's financial performance or strategic direction.

Solara Q3 FY26: Growth API Margins at 25% Amid Strategic Review of Ibuprofen Business

🔵 WATCH ⭐ 7/10

EARNINGS 📅 10 Feb 2026, 05:52 PM

Solara reported Q3 FY26 revenue of INR 346 crores, up 10% Q-o-Q, though consolidated gross margins fell to 47% due to headwinds in the base ibuprofen business. The non-ibuprofen 'growth' segment is performing exceptionally well with 56% gross margins and 25% EBITDA margins, significantly outperforming the commodity business. Management has initiated a strategic review of the ibuprofen division, which is currently utilizing only 3,000 tons of its 6,000-ton Pondicherry capacity. The company successfully reduced debt by INR 146 crores (19%) and targets a sub-INR 500 crore debt level by May 2026.

Revenue grew 10% Q-o-Q to INR 346 crores; EBITDA stood at INR 37 crores with an 11% margin.
Non-ibuprofen growth business achieved high-tier margins of 56% (gross) and 25% (EBITDA).
Ibuprofen capacity utilization remains low at 50% for the Pondicherry plant (3,000 of 6,000 tons).
Debt was reduced by INR 146 crores (19%) during the quarter, aided by rights issue proceeds.
A one-time exceptional cost of INR 6.7 crores was incurred due to the new labor wage code implementation.

💡 Investors should closely monitor the Q4 announcement regarding the strategic review of the ibuprofen business, as a potential restructuring or hive-off could unlock significant value from the high-margin growth API segment.

Solara Active Pharma Releases Q3 FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 06 Feb 2026, 06:51 PM

Solara Active Pharma Sciences has officially released the audio recording of its Q3 FY26 earnings conference call held on February 06, 2026. The call provided management commentary on the company's financial performance for the quarter and nine-month period ending December 31, 2025. This disclosure is a routine regulatory requirement under SEBI LODR regulations to ensure transparency for all shareholders. Investors can access the full recording on the company's website to understand the business outlook and operational updates.

Audio recording of the Q3 FY26 earnings call made available on February 06, 2026.
Covers financial and operational performance for the nine months ended December 31, 2025.
Compliant with SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations 30 and 46.
Direct link to the audio file provided for immediate investor access via the corporate website.

💡 Investors should listen to the recording to evaluate management's guidance on API market recovery and debt reduction plans. This is a routine update and does not require immediate trading action unless specific material surprises were noted during the call.

Solara Reports Zero Deviation in ₹308.85 Cr Rights Issue Fund Utilization

🟢 POSITIVE ⭐ 6/10

REGULATORY 📅 06 Feb 2026, 02:38 PM

Solara Active Pharma Sciences has confirmed that there is no deviation or variation in the utilization of ₹308.85 crores raised through its Rights Issue as of December 31, 2025. The company has primarily used the proceeds for debt reduction, with ₹233.61 crores allocated to the repayment or pre-payment of borrowings. Additionally, ₹74.97 crores have been utilized for general corporate purposes out of a total planned allocation of ₹112.24 crores. The Audit Committee and monitoring agency CRISIL have reviewed and approved these statements without any adverse comments.

Total funds raised through the Rights Issue amounted to ₹308.85 crores as of December 31, 2025.
A significant portion of ₹233.61 crores was utilized for the repayment or pre-payment of outstanding borrowings.
₹74.97 crores were deployed for General Corporate Purposes (GCP), adhering to the 25% cap of gross proceeds.
The company reported zero deviation from the objects mentioned in the Letter of Offer dated May 09, 2024.
A minor balance of ₹0.26 crores remains in the escrow account to be utilized in upcoming quarters.

💡 Investors should take confidence in the company's disciplined use of capital for debt reduction, which should improve the balance sheet. Monitor upcoming earnings reports to see the positive impact of reduced interest costs on the bottom line.

Solara Active Pharma Updates Materiality and Related Party Transaction Policies

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 06 Feb 2026, 02:19 PM

Solara Active Pharma Sciences has updated its internal governance policies following a Board meeting on February 06, 2026. The revisions specifically target the Policy for Determining Materiality of Events and the Policy for Governance of Related Party Transactions. These changes are designed to align the company's internal frameworks with recent amendments to SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations. While these are procedural updates, they reflect the company's commitment to regulatory compliance and transparency in reporting.

Board approved amendments to the Policy for Determining Materiality of Events under Regulation 30 of SEBI LODR
Revised Policy for Governance of Related Party Transactions adopted to comply with Regulation 23 of SEBI LODR
The updates were finalized during the Board meeting held on February 06, 2026
Both amended policies are now available for public viewing on the company's official website

💡 This is a routine regulatory update and requires no immediate action from investors. Monitor the company's website for specific details of the revised policies to assess governance standards.

Solara Q3 FY26 Revenue Up 15% to ₹3,490M; Board to Evaluate Ibuprofen Business Options

🔵 WATCH ⭐ 8/10

EARNINGS 📅 06 Feb 2026, 02:09 PM

Solara reported a 15% YoY revenue growth to ₹3,490 million in Q3 FY26, driven by its high-margin Growth API segment which achieved a 24.7% EBITDA margin. However, the company posted a net loss of ₹174 million as the commodity Ibuprofen business remains a significant drag with negative EBITDA margins of -22.9%. To address this structural challenge, the Board is appointing strategic advisors to evaluate options for the Ibuprofen business and re-assess the previously announced CRAMS split. Debt reduction is on track, with gross debt falling to ₹6,300 million from ₹7,760 million in March 2025.

Revenue grew 15% YoY to ₹3,490 million, though EBITDA fell 37% YoY to ₹374 million due to Ibuprofen pricing pressures.
Growth API segment (Ex-Ibuprofen) delivered strong performance with 56.3% gross margins and ₹608 million EBITDA.
Ibuprofen base business reported an EBITDA loss of ₹234 million for the quarter, prompting a strategic review.
Gross debt reduced to ₹6,300 million as of December 2025, with a target to reach ₹4,999 million by May 2026.
Board is re-evaluating the CRAMS & Polymers business split scheme with a new roadmap expected next quarter.

💡 Investors should closely monitor the upcoming strategic roadmap for the Ibuprofen business, as a potential divestment or restructuring could unlock value by isolating the high-growth, high-margin API portfolio.

Solara Active Pharma Q3 Revenue Grows to ₹349 Cr; Net Loss Widens to ₹17.43 Cr

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 06 Feb 2026, 01:47 PM

Solara Active Pharma reported a 16% YoY revenue growth to ₹349 crore for Q3 FY26, but the company's financial health remains under significant pressure. The net loss widened to ₹17.43 crore, impacted by a ₹6.75 crore exceptional item related to new labor codes. Concerns persist regarding liquidity as net current liabilities exceed assets by ₹92.44 crore, with accumulated losses reaching ₹329.64 crore. The company is banking on a pending ₹134.99 crore rights issue call to stabilize its capital position.

Revenue from operations rose to ₹349.00 crore in Q3 FY26 from ₹300.31 crore in Q3 FY25.
Net loss for the quarter stood at ₹17.43 crore versus a profit of ₹8.09 crore in the previous year's corresponding quarter.
Exceptional loss of ₹6.75 crore recorded due to gratuity and compensated absences impact under new labor codes.
Net current liabilities exceed net current assets by ₹92.44 crore as of December 31, 2025.
Company plans to raise ₹134.99 crore through the final call of its pending rights issue to fund operations.

💡 Investors should exercise caution given the widening losses and the 'going concern' notes regarding liquidity and working capital deficits. The stock's recovery depends heavily on the successful completion of the rights issue and a significant turnaround in operational margins.

Solara Pharma Issues Second Reminder for ₹131.25 First Call Money Payment

🟡 NEUTRAL ⭐ 6/10

FUNDRAISE 📅 04 Feb 2026, 11:06 PM

Solara Active Pharma Sciences has issued a second reminder notice for the payment of the First Call Money related to its Rights Issue. Shareholders holding partly paid-up shares are required to pay ₹131.25 per share, which includes ₹3.50 towards face value and ₹127.75 towards premium. The payment window is scheduled from February 5, 2026, to February 19, 2026. Upon successful payment, shares will be converted from a paid-up value of ₹3.50 to ₹7.00.

First Call Money amount is set at ₹131.25 per partly paid-up equity share
Payment period runs for 15 days from February 5, 2026, to February 19, 2026
Failure to pay will result in the forfeiture of shares and any amount already paid
Successful payment upgrades shares to ₹7.00 partly paid-up status under ISIN IN9624Z01022
Payments must be made electronically via the dedicated RTA portal using Net Banking or UPI

💡 Investors holding partly paid-up shares (ISIN: IN9624Z01014) must complete the payment by February 19, 2026, to prevent the forfeiture of their existing investment. Ensure the payment is made from the registered bank account to avoid rejection.

Solara Pharma Seeks Approval for Appointment of Mohanraj Sanjeevi as Whole-time Director

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 04 Feb 2026, 10:50 PM

Solara Active Pharma Sciences has issued a postal ballot notice to seek shareholder approval for the appointment of Mr. Mohanraj Sanjeevi as a Whole-time Director. The appointment is proposed for a three-year term effective from January 1, 2026, to December 31, 2028. The proposed remuneration package includes a fixed component of ₹85 lakh and a variable component of ₹15 lakh per annum. Shareholders can participate in the e-voting process from February 5 to March 6, 2026, with final results expected by March 10, 2026.

Appointment of Mr. Mohanraj Sanjeevi as Whole-time Director for a 3-year term starting January 1, 2026.
Proposed annual remuneration consists of ₹85,00,000 fixed pay and ₹15,00,000 variable pay.
Annual increments are capped at a maximum of 30% of the last drawn remuneration.
E-voting period is scheduled from February 5, 2026, to March 6, 2026.
The resolution is being proposed as a Special Resolution via electronic postal ballot.

💡 This is a routine management appointment and requires no immediate action from investors other than participating in the e-voting process if they wish to exercise their rights. Monitor the voting results on March 10, 2026, to confirm the formalization of the executive leadership.

Solara Active Pharma Reschedules Q3 FY26 Earnings Call to Feb 6 at 3:30 PM

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 03 Feb 2026, 03:03 PM

Solara Active Pharma Sciences has announced a change in the timing of its upcoming earnings conference call. The call, intended to discuss the unaudited financial results for the quarter and nine months ended December 31, 2025, is now scheduled for Friday, February 6, 2026, at 3:30 PM IST. This is a one-hour advancement from the previously announced time of 4:30 PM IST. Key leadership, including the Founder, MD & CEO, and CFO, will be present to interact with analysts and investors.

Conference call rescheduled to February 6, 2026, at 3:30 PM IST
Call time advanced by 60 minutes from the original 4:30 PM schedule
Focus of the call is the unaudited financial results for Q3 and 9M FY26
Management participation includes Founder Arun Kumar, MD & CEO Sandeep Rao, and CFO Sarat Kumar
Universal access dial-in numbers provided: +91 22 6280 1346 and +91 22 7115 8247

💡 Investors and analysts planning to attend the call should update their schedules for the earlier 3:30 PM start time. Monitor the call for management commentary on API segment growth and margin recovery.

Solara Active Pharma Schedules Q3 FY26 Earnings Call for February 6, 2026

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 30 Jan 2026, 08:31 PM

Solara Active Pharma Sciences has scheduled its earnings conference call for February 6, 2026, at 4:30 PM IST. The management team will discuss the unaudited financial results for the quarter and nine months ended December 31, 2025. The call will feature key leadership including Founder Arun Kumar and CEO Sandeep Rao, providing an opportunity for analysts to probe the company's operational performance. This is a routine but essential event for understanding the company's current trajectory in the API segment.

Conference call set for Friday, February 6, 2026, at 4:30 PM IST
Agenda includes discussion of unaudited financial results for Q3 and 9M FY26
Participation confirmed from Founder Arun Kumar, MD & CEO Sandeep Rao, and CFO Sarat Kumar
Universal dial-in numbers provided are +91 22 6280 1346 and +91 22 7115 8247

💡 Investors should monitor the upcoming financial results and the subsequent management commentary for updates on margin improvements and API business growth. No immediate action is necessary based on this scheduling announcement alone.

Solara Active Pharma Complies with SEBI Demat Regulations for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 12 Jan 2026, 03:42 PM

Solara Active Pharma Sciences has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations for the period ended December 31, 2025. The company's Registrar and Share Transfer Agent, Cameo Corporate Services Limited, confirmed that all share certificates received for dematerialization were processed within the stipulated time limits. The process involved the mutilation and cancellation of physical certificates and updating the depository names in the register of members. This is a standard regulatory filing confirming the integrity of the company's shareholding records.

Compliance certificate issued for the quarter ended December 31, 2025.
Registrar Cameo Corporate Services confirmed timely processing of all dematerialization requests.
Physical security certificates were mutilated and cancelled after due verification.
Company records updated to reflect depositories as registered owners within the required timeframe.

💡 No action is required as this is a routine administrative filing. Investors should continue to monitor the company's upcoming quarterly financial performance for material updates.

Solara Active Pharma to Close Trading Window from Jan 1, 2026, for Q3 FY26 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 24 Dec 2025, 01:05 PM

Solara Active Pharma Sciences Limited has announced the closure of its trading window for all designated persons starting January 1, 2026. This closure is a standard regulatory requirement under SEBI (Prohibition of Insider Trading) Regulations, 2015, preceding the announcement of financial results. The window will remain closed for the quarter and nine months ending December 31, 2025. It is scheduled to reopen 48 hours after the financial results are declared to the exchanges.

Trading window closure effective from Thursday, January 1, 2026
Pertains to financial results for the quarter and nine months ended December 31, 2025
Window to remain closed until 48 hours post-declaration of results
Board meeting date for results declaration to be announced in due course

💡 No action is required as this is a routine regulatory compliance filing. Investors should monitor for the upcoming board meeting date to assess the company's Q3 FY26 performance.

Solara Active Pharma Allots 1,500 Equity Shares via ESOP at Rs. 375/Share

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 17 Dec 2025, 11:49 AM

Solara Active Pharma Sciences has approved the allotment of 1,500 equity shares following the exercise of options under its 2018 ESOP scheme. The shares were issued at an exercise price of Rs. 375 per share, resulting in a total capital realization of Rs. 5.62 lakh. This allotment increases the total paid-up share count to 4,81,71,562 shares. The dilution is negligible, with a reported impact of Rs. 0.10 on diluted earnings per share.

Allotment of 1,500 equity shares of face value Rs. 10 each.
Exercise price set at Rs. 375 per share, including a premium of Rs. 365.
Total funds realized by the company from this exercise amount to Rs. 5,62,500.
Total paid-up share capital increased to 4,81,71,562 shares post-allotment.
The new shares rank pari-passu with existing equity shares in all respects.

💡 This is a routine administrative update with minimal impact on the company's valuation or shareholding structure. No specific action is required from investors.

View All SOLARA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company operates as a pure-play API business. Total income was INR 1,294.29 Cr in FY24, a marginal decline of 0.2% YoY from INR 1,466.36 Cr in FY23. Q2 FY26 revenue was INR 314 Cr, representing a 10% YoY decline from INR 347.2 Cr in Q2 FY25 and a 2% QoQ decline from INR 320.1 Cr in Q1 FY26.

Geographic Revenue Split

Regulated markets remain the primary revenue driver, contributing 75% of overall sales in Q2 FY26, compared to 77% in Q1 FY26 and 76% in Q2 FY25. This concentration in regulated markets ensures higher quality standards but increases exposure to US FDA and EMA regulatory actions.

Profitability Margins

Gross margins remained resilient at 51% in Q2 FY26, though this was a 264 bps decline QoQ due to changes in the product mix. Net profitability saw a massive recovery from a PAT loss of INR 566.96 Cr in FY24 (PAT margin -43.97%) to a positive PAT of INR 0.54 Cr in FY25.

EBITDA Margin

EBITDA margin recovered to 16.5% (INR 213.84 Cr) in FY25 from a negative 7.1% (INR -92.03 Cr) in FY24. However, Q2 FY26 EBITDA margin dropped to 11.3% (INR 35.2 Cr), a 673 bps YoY decrease from 18.0% in Q2 FY25, driven by operational disruptions and one-time costs.

Capital Expenditure

The company has focused on debt reduction and equity infusion rather than large-scale new CapEx. Net debt to equity improved from 1.1x in FY24 to 0.7x in FY25. Specific investments include upgrading Effluent Treatment Plants (ETPs) and a INR 4 Cr facility upgradation at the Mangalore site.

Credit Rating & Borrowing

CRISIL maintains a Negative/Stable outlook. Interest coverage improved significantly to 2.12x in FY25 from -0.89x in FY24. Term debt obligations are approximately INR 100-117.25 Cr per annum, with bank limit utilization high at 95.68% as of late 2023.

⚙️ Operational Drivers

Raw Materials

Key raw materials include chemical intermediates for anthelmintic, anti-malaria, and NSAID APIs. While specific chemical names are not listed, raw material procurement and inventory levels are currently planned for sales exceeding INR 350 Cr per quarter.

Import Sources

Not specifically disclosed, though the company notes significant price competition from Chinese suppliers, implying China is a major sourcing or competitive benchmark region.

Capacity Expansion

The Vizag facility is currently 'mothballed' and will only resume operations once CRAMS (Contract Research and Manufacturing Services) partnerships are secured. The Mangalore facility recently underwent an unscheduled shutdown for facility upgradation.

Raw Material Costs

Raw material costs are a significant driver of the 49% cost of goods sold (implied by 51% gross margin). Deferred deliveries of high-margin products led to an inventory buildup of raw materials, increasing current liabilities.

Manufacturing Efficiency

Operational challenges in Q2 FY26 led to deferred deliveries of products worth INR 30-35 Cr. The company is focusing on network optimization and opex leverage to improve efficiency.

📈 Strategic Growth

Expected Growth Rate

12%

Growth Strategy

The company aims to pivot from a stable phase to a growth phase by targeting quarterly revenues of INR 350 Cr+. Key strategies include expanding the CRAMS business (Vizag plant), increasing focus on the non-steroidal anti-inflammatory (NSAID) segment, and reducing debt through equity infusions and rights issues.

Products & Services

Active Pharmaceutical Ingredients (APIs) for therapeutic segments including anthelmintic, anti-malaria, anti-infective, and non-steroidal anti-inflammatory drugs (NSAIDs) like Ibuprofen.

Brand Portfolio

Solara Active Pharma Sciences.

New Products/Services

The company is granting 3,50,000 stock options under the ESOP 2024 plan to align management with new product development and business expansion goals.

Market Expansion

Focusing on increasing market share in regulated markets (currently 75% of revenue) and diversifying the API portfolio into new therapeutic segments.

Market Share & Ranking

Positioned as a key player in the global API market, particularly in specialized segments like anthelmintics and NSAIDs.

Strategic Alliances

Actively seeking partnerships for the CRAMS division to utilize the currently mothballed Vizag facility.

🌍 External Factors

Industry Trends

The API industry is seeing a shift toward 'China+1' sourcing strategies, which Solara is positioned to benefit from, provided it maintains its 'stellar compliance record' and manages its 16.5% EBITDA margin targets.

Competitive Landscape

Faces intense competition from large-scale Chinese API manufacturers and other Indian pure-play API companies.

Competitive Moat

Moat is built on management's extensive experience, a robust compliance framework, and a 75% revenue contribution from high-entry-barrier regulated markets. Sustainability depends on avoiding further operational 'one-offs'.

Macro Economic Sensitivity

Highly sensitive to global pharmaceutical demand and healthcare regulatory shifts in the US and Europe.

Consumer Behavior

Demand is driven by global pharmaceutical companies' needs for high-quality, compliant API sources for generic and branded drugs.

Geopolitical Risks

Trade barriers or increased scrutiny on Indian API manufacturing sites by foreign regulators (US FDA) pose a constant risk to the export-heavy model.

⚖️ Regulatory & Governance

Industry Regulations

Strict adherence to global cGMP standards is mandatory. Most products face inspections from the US FDA; any adverse observations (Warning Letters) can halt sales to the US market.

Environmental Compliance

Requires continuous investment in Effluent Treatment Plants (ETPs) to manage waste discharge; non-compliance poses a risk to manufacturing licenses.

Legal Contingencies

The company states there are no significant or material orders passed by regulators or courts that impact its status as a going concern as of March 31, 2025.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the frequency of 'one-off' operational disruptions (fire, unscheduled shutdowns) which have historically caused EBITDA to swing from 16.5% to -7.1%.